ObjectivesPharmacovigilance education is essential since adverse drug reactions (ADRs) are a serious health problem and contribute to unnecessary patient burden and hospital admissions. Healthcare professionals have little awareness of pharmacovigilance and ADR reporting, and only few educational interventions had durable effects on this awareness. Our future healthcare providers should therefore acquire an adequate set of pharmacovigilance competencies to rationally prescribe, distribute, and monitor drugs. We investigated the pharmacovigilance and ADR-reporting competencies of healthcare students to identify educational interventions that are effective in promoting pharmacovigilance.MethodsThe PubMed, EMBASE, Cochrane, CINAHL, PsycINFO, and ERIC databases were searched using the terms “pharmacovigilance,” “students,” and “education.”.ResultsTwenty-five cross-sectional and 14 intervention studies describing mostly medical and pharmacy students were included. Intentions and attitudes on ADR reporting were overall positive, although most students felt inadequately prepared, missed the training on this topic, and lacked basic knowledge. Although nearly all students observed ADRs during clinical rounds, only a few had actually been involved in reporting an ADR. Educational interventions were predominately lectures, sometimes accompanied by small interactive working groups. Most interventions resulted in a direct increase in knowledge with an unknown long-term effect. Real-life learning initiatives have shown that healthcare students are capable of contributing to patient care while increasing their ADR-reporting skills and knowledge.ConclusionsThere is an urgent need to improve and innovate current pharmacovigilance education for undergraduate healthcare students. By offering real-life pharmacovigilance training, students will increase their knowledge and awareness but can also assist current healthcare professionals to meet their pharmacovigilance obligations.Electronic supplementary materialThe online version of this article (10.1007/s00228-018-2500-y) contains supplementary material, which is available to authorized users.

Clinical Therapeutics e64 Volume 39 Number 8S despite demonstrated bioequivalence between the used formulations. Following further optimisation and validation of the Pmetrics model, we plan to perform simulations to investigate the extent of the influence of these subpopulations on the pharmacokinetic similarity between the bioequivalent formulations.